Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate
Perth, AUSTRALIA and Chengdu, CHINA – 19 June 2020 -- Clover Biopharmaceuticals today announced that the first participants have been dosed in the Phase 1 first-in-human study evaluating the company’s
Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19
MIAMI--(BUSINESS WIRE)--June 19, 2020 -- Ridgeback Biotherapeutics announces the launch of two Phase 2 clinical trials to test the efficacy of EIDD-2801 as an anti-viral treatment for COVID-19. Phase
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following Giroctocogene Fitelparvovec (SB-525) Gene Therapy
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE) June 18, 2020 -- Pfizer Inc. (NYSE:PFE)andSangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
London: Thursday, June 18, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation
Genentech’s IPATential150 Study Evaluating Ipatasertib in Combination With Abiraterone and Prednisone/Prednisolone Met One of Its Co-Primary Endpoints
South San Francisco, CA -- June 18, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IPATential150 study met its co-primary endpoint of r
FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
KENILWORTH, N.J.--(BUSINESS WIRE) -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a solub
CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate
TÜBINGEN, Germany/ BOSTON -- June 17, 2020 -- CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that th
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
SAN RAFAEL, Calif., June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 s
Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19
Foster City, Calif., June 17, 2020 – Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences: “From the onset of the pandemic, Gilead h
Cobra Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate
June 16, 2020 -- Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK
Imperial to Begin First Human Trials of New COVID-19 Vaccine
LONDON, June 15, 2020 -- Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London. The study will be the first time
Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients
Burlingame, CA, June 15, 2020 -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s prop
News
- CanalLotus Biotech -
Int'l Clinical Service Expert
We are the leader
Because of our professionism
